Your browser doesn't support javascript.
loading
Should non-invasive diffuse main-duct intraductal papillary mucinous neoplasms be treated with total pancreatectomy?
Blair, Alex B; Beckman, Ross M; Habib, Joseph R; Griffin, James F; Lafaro, Kelly; Burkhart, Richard A; Burns, William; Weiss, Matthew J; Cameron, John L; Wolfgang, Christopher L; He, Jin.
Afiliação
  • Blair AB; Johns Hopkins Medical Institutions and the Pancreatic Cancer Precision Medicine Center of Excellence Program, Baltimore, MD, USA.
  • Beckman RM; Johns Hopkins Medical Institutions and the Pancreatic Cancer Precision Medicine Center of Excellence Program, Baltimore, MD, USA.
  • Habib JR; Johns Hopkins Medical Institutions and the Pancreatic Cancer Precision Medicine Center of Excellence Program, Baltimore, MD, USA.
  • Griffin JF; Johns Hopkins Medical Institutions and the Pancreatic Cancer Precision Medicine Center of Excellence Program, Baltimore, MD, USA.
  • Lafaro K; Johns Hopkins Medical Institutions and the Pancreatic Cancer Precision Medicine Center of Excellence Program, Baltimore, MD, USA.
  • Burkhart RA; Johns Hopkins Medical Institutions and the Pancreatic Cancer Precision Medicine Center of Excellence Program, Baltimore, MD, USA.
  • Burns W; Johns Hopkins Medical Institutions and the Pancreatic Cancer Precision Medicine Center of Excellence Program, Baltimore, MD, USA.
  • Weiss MJ; Department of Surgery, Northwell Health, Manhasset, NY, USA.
  • Cameron JL; Johns Hopkins Medical Institutions and the Pancreatic Cancer Precision Medicine Center of Excellence Program, Baltimore, MD, USA.
  • Wolfgang CL; Department of Surgery, New York University, New York, NY, USA.
  • He J; Johns Hopkins Medical Institutions and the Pancreatic Cancer Precision Medicine Center of Excellence Program, Baltimore, MD, USA. Electronic address: jhe11@jhmi.edu.
HPB (Oxford) ; 24(5): 645-653, 2022 05.
Article em En | MEDLINE | ID: mdl-34610896
ABSTRACT

BACKGROUND:

Main-duct (MD) intraductal papillary mucinous neoplasm (IPMN) is associated with malignancy risk. There is a lack of consensus on treatment (partial or total pancreatectomy) when the MD is diffusely involved. We sought to characterize the pancreatic remnant fate after partial pancreatectomy for non-invasive diffuse MD-IPMN.

METHODS:

Consecutive patients with partial pancreatectomy for non-invasive MD-IPMN from 2004 to 2016 were analyzed. Diffuse MD-IPMN was defined by preoperative imaging as dilation of the MD in the head of the pancreas more than 5 mm and involving the whole gland.

RESULTS:

Of 127 patients with resected non-invasive MD-IPMN, 47 (37%) had diffuse MD involvement. Eleven of 47(23%) patients developed imaging evidence of progression or new cystic disease in the pancreatic remnant. Patients with diffuse MD-IPMN were older (73yrs vs 67yrs, p = 0.009), more likely to receive a pancreaticoduodenectomy (96% vs 56%, p < 0.001) and have high-grade dysplasia (51% vs 31%, p = 0.025) than those with focal MD involvement. Diffuse MD involvement was not associated with shorter PFS following partial pancreatectomy (p = 0.613).

CONCLUSION:

Partial pancreatectomy is an appropriate surgical approach for diffuse MD-IPMN, and is not associated with earlier progression after surgery as compared to partial pancreatectomy for focal dilation.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Adenocarcinoma Mucinoso / Carcinoma Ductal Pancreático / Neoplasias Intraductais Pancreáticas Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Adenocarcinoma Mucinoso / Carcinoma Ductal Pancreático / Neoplasias Intraductais Pancreáticas Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article